Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer

Inclusion Criteria

• •1. Women of more than 18 years old (menopausal or not)
• •2. Women with metastatic invasive breast cancer or locally advanced (without surgical project), for which treatment with tamoxifen or anti aromatase
• •+/- LH-RH agonist, is indicated (anti-aromatase prescribed for menopausal womens; tamoxifen prescribed for both menopausal, pre menopausal or not menopausal womens).
• •3. Cancer hormone-expressing estrogen receptor (ER) and / or progesterone receptor (PR) (\>= 10% of tumor cells by IHC technique).
• •Cancer HER2 negative.
• •4. Evaluable disease (measurable according RECIST criteria or not)
• •5. Any previous adjuvant hormone therapy should be discontinued for at least 21 days.
• •6. One or two prior metastatic lines of chemotherapy are allowed
• •7. General status WHO 0-2
• •8. The women of childbearing age must use an effective contraception for the duration of the study
• •9. Informed consent obtained and signed before any specific study procedure
• •10. Patient member in a national insurance scheme